摘要
目的探讨选择性COX-2抑制剂Ethodolac对人舌癌细胞SAS的增殖和浸润能力的抑制作用。方法将人低分化舌鳞状上皮细胞癌细胞株(SAS)与不同浓度的选择性COX-2抑制剂Ethodolac共同培养,染色后测定595nm下的吸光度。比较不同浓度Ethodolac下的细胞增殖情况。同时,利用Boyden小室测定Ethodolac对SAS细胞浸润能力的影响。结果Ethodolac可以明显降低SAS细胞的增殖和浸润能力(P<0.05),作用效果呈现时间剂量依赖关系。结论本研究为COX-2在肿瘤发生、发展中的作用提供了一定依据,而且也通过COX-2选择性抑制剂Ethodolac对人舌癌细胞SAS增殖和浸润的抑制,提示选择性COX-2抑制剂在口腔癌的预防和治疗中的作用前景。
Objective COX-2 over-expression has been found in tumors of various kinds, and the use of COX-2 inhibitors also has been shown to be effective in the therapy of some kinds of cancers. However, the effect of COX-2 inhibitors on oral cancer cell has not been well studied. Methods One oral cancer cell line (SAS) was used in the present study. The selective COX-2 inhibitor Etodolac was used as the COX-2 inhibitor. In the proliferation assay, the cells were cultured with media containing Etodolac of different concentration for 72 hours. The amount of living cells was estimated and compared by exam with an autoplate reader. The invasion assay was done using the BD biocoat Matrigel Invasion Chamber when the cells were cultured with 10^-2-10^-6 mg/ml Etodolac. Results The results of proliferation assay showed that in all groups containing Etodolac, the amount of living cell was decreased, and the effect was in a dose dependent pattern. The invasion assay indicated that Etodolac could effectively decrease the cell invasion ability. The result of ELISA showed the concentration of VEGF was decreased in the Etodolac containing groups.Conclusion COX-2 inhibitors appear to be effective to oral cancer cell, and may become potential way for the therapy of cancer.
出处
《广东牙病防治》
2005年第3期186-188,共3页
Journal of Dental Prevention and Treatment